1 January 2022 in International Journal Of Clinical Practice
Introduction. The fibrosis 4 (FIB‐4) index was developed to predict advanced fibrosis in patients with liver disease. We aimed to evaluate the association of FIB‐4 with risk factors for progression to critical illness in middle‐aged patients hospitalized for coronavirus disease 2019 (COVID‐19). Method. We included patients aged 35–65 years who were hospitalized following a positive RT‐PCR SARS‐Cov‐2 test in a tertiary hospital. All data were obtained from the medical records of the patients during the first admission to the hospital. The FIB‐4 index was calculated according to the equation (age (years) x AST (IU/L)/platelet count (109/L)/√ALT (IU/L)). The FIB‐4 index was divided into three categories according to the score categorisation: 2.67 = high risk. Results. A total of 619 confirmed COVID‐19 patients (mean age = 52 yrs.) were included in this study; 37 (6.0%) were admitted to the intensive care unit (ICU), of which 44% were intubated and eight (1.3%) patients died during follow‐up. The results of patients with high FIB‐4 scores were compared with those with low FIB‐4 scores. In patients with high FIB‐4 scores, male gender, and advanced age, decreased neutrophil, lymphocyte, thrombocyte, and albumin counts, elevated AST, LDH, CK, ferritin, CRP, and D‐dimer, and low GFR were the high‐risk factors for critical illness. Additionally, the number of patients referred to ICU with high FIB‐4 who died had higher scores than from those with low scores. Conclusion. The FIB‐4 index derived from baseline data obtained during hospitalisation can be used as a simple, inexpensive, and straightforward indicator to predict ICU requirement and/or death in middle‐aged hospitalized COVID‐19 patients.
19 September 2023 in Bagcilar Medical Bulletin
15 December 2019 in Turkish Journal of Gastroenterology
Background/Aims: There is an increased tendency for thrombosis and thromboembolic complications in patients with inflammatory bowel disease (IBD). The aim of the present study was to determine the serum concentrations of thrombin-activatable fibrinolysis inhibitor (TAFI), tissue factor pathway inhibitor (TFPI) and a disintegrin and metalloproteinase with thrombospondin motif-13 (ADAMTS-13) in patients with IBD and to assess their possible role in the etiopathogenesis of the disease. Materials and Methods: Thirty-four patients with IBD (23 ulcerative colitis and 11 Crohn’s disease) and 20 healthy controls were included in the present study. TAFI, TFPI, and ADAMTS-13 concentrations were determined by enzyme-linked immunosorbent assay. Results: Mean TAFI, TFPI, and ADAMTS-13 concentrations in the patient group were 17.75 ng/ml, 72.10 ng/ml, and 14.90 U/l, respectively. In the control group, these values were 117.10 ng/ml, 300 ng/ml, and 191.55 U/l, respectively. TAFI, TFPI, and ADAMTS-13 values were significantly lower in the patient group than in the control group (all p<0.01). Conclusion: TAFI, TFPI, and ADAMTS-13 levels were significantly lower in the patient group. These findings indicate the presence of a clear, multifactorial imbalance in the coagulation–fibrinolytic system in the patient group. It is also possible that this imbalance in the coagulation and fibrinolytic system may play a role in the still unclear etiopathogenesis of the disease.
27 September 2023 in Medical Bulletin of Haseki